Laurie Toich, Assistant Editor

Genentech’s Lucentis granted fifth FDA approval.

Lucentis was recently approved to treat myopic choroidal neovascularization.

The FDA approved the lowest amount of new drugs since 2010 last year, with only 22 new drugs receiving approval.

The survey found 65.5% of veterans experienced pain within the past 3 months.

ASN003 is a drug that targets cancers driven by BRAF and PI3K.

Top news of the day from across the healthcare landscape.

ASN003 demonstrated potent action against tumor growth.

The FDA only approved 22 new drugs in 2016, the lowest amount in years.

The FDA only approved 22 new drugs in 2016, the lowest amount in years.

A new report discusses how much the ACA repeal may cost and save the United States.

Hispanic newborns that develop acute lymphoblastic leukemia are 5.9% times more likely to have a cytomegalovirus infection at birth.

Purdue and Shionogi will co-launch Symproic to treat opioid-induced constipation.

Treatment with antihypertensive drugs was seen to lower cancer-related proteins.

Mice that exercised showed increased brain plasticity compared with those that did not.

Combination treatment methods to cure HIV may have harmful side effects.

Top news of the day from across the healthcare landscape.

The lawsuit alleges the FDA is holding the Criminal Justice Department’s import of thiopental sodium.

Novartis partners with Conatus to develop a new drug for non-alcoholic steatohepatitis.

Abbreviated new drug applications were accepted for 3 topical generic products on December 30, 2016.

Treatment with haloperidol may double mortality risk for patients with Alzheimer’s disease.

Prescription opioid misuse decreased by 45% over the past 5 years.

Metformin is recommended as the first-line therapy for patients with type 2 diabetes.

Top news of the day from across the healthcare landscape.

Premature death could potentially be prevented through psychological efforts.

Implementing expansive databases will provide states with a better view of the healthcare system.

Combination treatment with rilpivirine and dolutegravir demonstrated non-inferiority to other regimens.

Two-drug combination with rilpivirine and dolutegravir demonstrated non-inferiority to other HIV regimens.

The American Diabetes Association opposes the Affordable Care Act repeal without a replacement plan.

Michigan will implement the PMP AWARxE from Appriss Health.

The FDA approved nusinersen (Spinraza) for the treatment of patients with spinal muscular atrophy.